Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ExSyn is a synthetic biology company focused on the development and commercialization of cell-free protein synthesis (CFPS) technology. The company's platform enables the rapid production of complex proteins and enzymes that are often difficult to express in traditional cell-based systems. By bypassing the constraints of living cells, ExSyn aims to accelerate the design-build-test cycle for protein engineering and provide a scalable solution for the manufacturing of high-value biologics. Their technology is particularly suited for the production of toxic proteins, membrane proteins, and proteins containing non-canonical amino acids.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ExSyn.